Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate adjunctive therapy for seizures associated with Lennox-Gastaut syndrome
2023-506616-41-00Phase 3Authorised
- Sponsor
- SK Life Science, Inc.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of carisbamate in Lennox-Gastaut syndrome (LGS) (3 arms), sponsored by SK Life Science, Inc. Primary endpoint: Percentage change from baseline in countable drop seizure frequency. Planned start Mar 2023; status: authorised.
02
Drugs
carisbamate
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2023-506616-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506616-41-00.